Filter news by date News Tags - Any -News storyPress release Month MonthJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember Year Year20252024202320222021202020192018201720162015201420132012201120102009200820072006 Apply 7 . 18 . 2025 News story More than skin deep: the daily reality of atopic dermatitis 7 . 17 . 2025 Press release Galderma unveils final nine-month data showing lasting efficacy and patient satisfaction with its Injectable Aesthetics portfolio when addressing facial aesthetic changes after medication-driven weight loss 7 . 8 . 2025 News story Scratching the Surface: shedding light on a misunderstood skin disease 7 . 1 . 2025 Press release Galderma announces departure of its Chief Financial Officer 6 . 25 . 2025 News story Breaking through the surface of sensitive skin 6 . 25 . 2025 Press release Galderma initiates two new clinical trials investigating nemolizumab in patients with Systemic Sclerosis and Chronic Pruritus of Unknown Origin 6 . 23 . 2025 News story Acne Awareness Month: let’s talk about acne 6 . 18 . 2025 Press release ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years 6 . 17 . 2025 Press release Galderma establishes new U.S. headquarters in Miami and strengthens regional leadership 6 . 6 . 2025 News story Revolutionizing Atopic Dermatitis 2025 Conference: Galderma’s Scientific Presentations 6 . 6 . 2025 Press release RAD 2025: Long-term data on Nemluvio® (nemolizumab) demonstrate its favorable safety profile and sustained and increased improvements in itch and skin lesions in patients with atopic dermatitis up to two years 6 . 5 . 2025 News story International Congress of Dermatology 2025: Galderma’s Scientific Presentations 5 . 28 . 2025 Press release Galderma buys back shares worth CHF 233 million in the context of accelerated bookbuild offering Pagination Next page Next Page